Only few studies have been devoted to the actions of the renin-angiotensin system (RAS) in the human gastrointestinal tract. The present study was undertaken to elucidate the expression and action of RAS in the human esophageal mucosa. Mucosal specimens with normal histological appearance were obtained from healthy subjects undergoing endoscopy and from patients undergoing esophagectomy due to neoplasm. Gene and protein expressions of angiotensin II (Ang II) receptor type 1 (AT1) and type 2 (AT2) and angiotensin-converting enzyme (ACE) were analyzed. In vivo functionality in healthy volunteers was reflected by assessing transmucosal potential difference (PD). Ussing chamber technique was used to analyze the different effects of Ang II on its AT1 and AT2 receptors. Immunoreactivity to AT1 and AT2 was localized to stratum superficiale and spinosum in the epithelium. ACE, AT1, and AT2 were found in blood vessel walls. Transmucosal PD in vivo increased following administration of the AT1 receptor antagonist candesartan. In Ussing preparations mean basal transmural PD was Ϫ6.4 mV, epithelial current (Iep) 34 A/cm 2 , and epithelial resistance (R ep) 321 ⍀ ⅐ cm 2 . Serosal exposure to Ang II increased PD as a result of increased Iep, whereas Rep was constant. Ang II given together with the selective AT1-receptor antagonist losartan, or AT2 agonist C21 given alone, resulted in a similar effect. Ang II given in presence of the AT2-receptor antagonist PD123319 did not influence PD, but Iep decreased and Rep increased. In conclusion, Ang II receptors and ACE are expressed in the human esophageal epithelium. The results suggest that AT2-receptor stimulation increases epithelial ion transport, whereas the AT1 receptor inhibits ion transport and increases R ep. potential difference; epithelial current; epithelial resistance IT IS WELL KNOWN FROM TEXTBOOKS in physiology that the renin-angiotensin system (RAS) is a prominent regulator of body fluid balance and blood circulation. Only a few studies have been devoted to the presence and potential actions of RAS in the human gastrointestinal system (6, 8, 9, 13, 16, 21, 23) . In a previous study we demonstrated that a local RAS exists in the musculature of the distal human esophagus and that angiotensin II (Ang II) is a stimulator of esophageal contractions via the Ang II type 1 (AT 1 ) receptor. The results suggest that Ang II is involved in the physiological control of the human esophageal motor activity (6). During the course of that study it was occasionally noted that Ang II receptors existed also in the esophageal mucosa. The present study was undertaken to specifically elucidate the expression and localization of RAS in the esophageal mucosa. Today RAS not only is regarded as an endocrine system but can also be locally expressed and involve several bioactive angiotensinogen fragments. The octapeptide Ang II is still regarded to be the most prominent mediator and enzymatic capability of its formation as well as presence of its receptors in a tissue can be used as good indicators of potential physiological actions. In the present study Western blotting, immunohistochemistry, and RT-PCR were used to examine the presence of angiotensin-converting enzyme (ACE), the AT 1 , receptor as well as the Ang II type 2 (AT 2 ) receptor in the human esophageal mucosa. We can now report that there exists an intriguingly pronounced epithelial expression of these RAS components in the healthy esophageal mucosa. The in vivo functionality of esophageal mucosal Ang II receptors was tested by pharmacological interference with the AT 1 receptor during measurements of esophageal transmucosal potential difference (PD) in healthy volunteers. A pharmacological analysis on isolated esophageal mucosa in vitro was employed for elucidating type of effect in relation to subtype of Ang II receptor.
IT IS WELL KNOWN FROM TEXTBOOKS in physiology that the renin-angiotensin system (RAS) is a prominent regulator of body fluid balance and blood circulation. Only a few studies have been devoted to the presence and potential actions of RAS in the human gastrointestinal system (6, 8, 9, 13, 16, 21, 23) . In a previous study we demonstrated that a local RAS exists in the musculature of the distal human esophagus and that angiotensin II (Ang II) is a stimulator of esophageal contractions via the Ang II type 1 (AT 1 ) receptor. The results suggest that Ang II is involved in the physiological control of the human esophageal motor activity (6) . During the course of that study it was occasionally noted that Ang II receptors existed also in the esophageal mucosa. The present study was undertaken to specifically elucidate the expression and localization of RAS in the esophageal mucosa. Today RAS not only is regarded as an endocrine system but can also be locally expressed and involve several bioactive angiotensinogen fragments. The octapeptide Ang II is still regarded to be the most prominent mediator and enzymatic capability of its formation as well as presence of its receptors in a tissue can be used as good indicators of potential physiological actions. In the present study Western blotting, immunohistochemistry, and RT-PCR were used to examine the presence of angiotensin-converting enzyme (ACE), the AT 1 , receptor as well as the Ang II type 2 (AT 2 ) receptor in the human esophageal mucosa. We can now report that there exists an intriguingly pronounced epithelial expression of these RAS components in the healthy esophageal mucosa. The in vivo functionality of esophageal mucosal Ang II receptors was tested by pharmacological interference with the AT 1 receptor during measurements of esophageal transmucosal potential difference (PD) in healthy volunteers. A pharmacological analysis on isolated esophageal mucosa in vitro was employed for elucidating type of effect in relation to subtype of Ang II receptor.
MATERIALS AND METHODS

Subjects and Tissue Specimens
Biopsies for expression analyses. Healthy subjects (n ϭ 8, mean age 31 yr, range 25-62 yr, 1 woman) with no history of gastrointestinal disease volunteered to esophagogastric endoscopy with mucosal biopsy takings. In general, three biopsies were taken in the distal esophagus 2 cm above the gastroesophageal junction (Z line) and were used for histology, immunohistochemistry, Western blotting, and RT-PCR. Only subjects with normal mucosal appearance at endoscopy and at histological examination were included. Resected tissues (see below) were also used for expression analyses.
Mucosal specimens for functional analysis in vitro. For in vitro analysis using the Ussing chamber technique, mucosal specimens from the region distal to the midesophagus were obtained from 17 patients (mean age 62.2 yr, range 46 -80 yr, 4 women) undergoing radical surgery for malignancy at the esophagogastric junction. Since all specimens were obtained from patients with a neoplastic process, care was taken not to include tissue close to the pathological process. In addition to normal macroscopic appearance, the resected mucosal specimens used in Ussing chamber experiments were also confirmed normal by histology.
In vivo investigation. Thirteen healthy volunteers (mean age 30 yr, range 23-62 yr, 2 women) participated in the functional examinations. All subjects were without history of gastrointestinal disease and were Helicobacter pylori negative as tested by a 13 C-urea breath test.
Ethics
The study was approved by the University of Gothenburg Ethics Committee as well as by the Regional Ethical Review Board in Gothenburg and was performed in accordance with the Declaration of Helsinki. All participants taking part in the study were informed verbally as well as in writing and signed a consent form before inclusion.
Histology
Both endoscopic biopsies and samples of the resected mucosal specimens were fixed in buffered 4% formaldehyde, dehydrated, and embedded in paraffin. For evaluation of general morphology, 3-m sections were mounted on slides and stained with hematoxylin-eosin.
Immunohistochemistry
Sections for immunohistochemistry were deparaffinized and then boiled for 15 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval. The Immunocruz Staining System (Santa Cruz Biotechnology, Santa Cruz, CA) was used for the immunohistochemistry protocol. After inhibition of endogenous peroxidase activity, the slides were preincubated with serum block and then incubated with primary antibodies against ACE and AT 1 and AT2 receptors over 2 h in room temperature in dilutions of 1:100 (see Table 1 ). The primary antibody was raised in goat, rabbit, and goat, respectively (Santa Cruz Biotechnology). Control sections were incubated with normal goat or rabbit IgG 0.4 g/l instead of the primary antibody. After being washed, the slides were incubated with biotinylated secondary antibody and the complex was detected by use of horseradish peroxidase-streptavidin. The color was developed using 3,3Ј-diaminobenzidine.
Western Blot Analyses
Specimens were snap frozen in liquid nitrogen and kept frozen for later Western blot analysis of ACE and AT 1 and AT2 receptor expressions. The frozen specimens were sonicated in a PE buffer (10 mM potassium phosphate buffer, pH 6.8, and 1 mM EDTA) containing 10 mM 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate (CHAPS: Boehringer Mannheim, Mannheim, Germany) and protease inhibitor cocktail tablet Complete (Roche Diagnostics, Stockholm, Sweden). The homogenate was then centrifuged (10,000 g for 10 min at 4°C) and the supernatant was analyzed for protein content by the Bradford method and stored at Ϫ80°C (4). Samples were diluted in SDS buffer and heated at 70°C for 10 min before they were loaded on a NuPage 10% Bis-Tris gel, and electrophoresis was run with use of a MOPS buffer (Invitrogen, Lidingo, Sweden). One lane of each gel was loaded with prestained molecular weight standards (SeeBlue, NOVEX, San Diego, CA). Kidney extract (for ACE), pheochromocytoma (PC-12; for AT 1 receptor) and hepatocellular carcinoma (HepG2; for AT2 receptor) whole-cell lysates served respectively as positive controls (Santa Cruz Biotechnology). After the electrophoresis, the proteins were transferred to a polyvinylidene difluoride membrane (Amersham, Buckinghamshire, UK), which was incubated with ACE and AT 1 and AT2 receptor antibodies, (see Table  1 ). An alkaline phosphatase conjugated donkey anti-goat or goat anti-rabbit IgG antibody (Santa Cruz) and CDP-Star (Tropix, Bedford, MA) was used as a substrate to identify immunoreactive proteins by means of chemiluminescence. Images were captured by a Chemidox XRS cooled charge-coupled device camera and analyzed with Quantity One software (Bio-Rad Laboratories, Hercules, CA).
Reverse Transcriptase-Polymerase Chain Reaction
Biopsies were snap frozen in liquid nitrogen. The frozen tissue was homogenized and total RNA was extracted according to the methods suggested by the manufacturer, following phenol-chloroform extraction and ethanol precipitation. Reverse transcription from 2.5 g of total RNA was carried out by using the SUPERSCRIPT First-Strand Synthesis System (Invitrogen, Lidingö, Sweden) with oligo(dT) Primers (Life Technologies, Täby, Sweden). Resulting cDNA was stored at Ϫ20°C until use. Lightcycler Q-PCR (Roche Diagnostics) was performed using the FastStart DNA Master SYBR Green I (Roche Diagnostics). PCR was performed containing 2 l of each RT sample by the hot-start technique. MgCl 2 concentration was optimized to 4 mM to obtain the highest signal intensity and lowest background. For each tested sample the copy number of the PCR products was calculated by dividing these values by the total RNA concentration as an internal standard, measured by use of a GENios spectrophotometer (TECAN, Salzburg, Austria). Copy numbers of target genes were then expressed as copy number per microgram total RNA (27) . The quantification was carried out by the software supplied by Roche Diagnostics (Mannheim, Germany). The primer sequences, PCR products sizes, and references are listed in Table 1 .
Transmucosal PD Recordings In Vivo
This setup has been described in more detail previously (6) . Briefly, after an overnight fast the subjects were supplied with a nasogastric catheter (Ch12) with 15 sideholes at 1 cm interdistance (customized E57, Dentsleeve Mui Scientific, Mississauga, ON, Canada). The catheter was fixated at one nostril and so positioned that it straddled the esophagogastric junction, leaving four to five sideholes in the gastric lumen and the rest in the distal esophagus. Each sidehole was connected to a pressure transducer that was separately fed with a low flow of 150 mM NaCl (3 ml/h). In addition, each pressure recording line (thus electrically isolated from each other) was used as an electrode for electrical potential recording via and Ag-AgCl bridge connected to a high-impedance voltmeter with a reference electrode positioned subcutaneously. Thus both the intraluminal hydrostatic pressure and transmucosal electrical PD at each sidehole were displayed online and stored for later analysis on a Macintosh personal computer (Apple Computers) using specially designed software (LabVIEW, National Instruments, Austin, TX). The sidehole recordings were plotted as a function of the distance from the nostril, thus allowing highresolution manometry of the distal esophagus as well as identification the squamocolumnar mucosal transition (observed as a step up in PD from esophageal mucosal values, typically being 12-15 mV, to that of gastric mucosa, typically 25-50 mV). In addition, the subjects were supplied with a dental oral suction device and instructed to avoid swallowing during the recordings.
The subjects participated at 2 separate study days, in a randomized fashion either without or with pretreatment with the AT 1 receptor antagonist candesartan (16 mg) ingested at 2200 the evening before the experiment. This time and dose was chosen on the basis of previous reports on plasma concentration and functional AT 1 receptor interference, the latter assessed as effects on renin-release (2, 11). After intubations and identification of the high-pressure zone as well as the PD step-up, the subjects were left for 30 min to allow basal conditions to be established. A modified Bernstein-test was then performed by infusion of 100 mM HCl ϩ 50 mM NaCl (the latter to achieve isotonicity) into the midesophagus at 2 ml/min over 20 min followed by 150 mM NaCl at 2 ml/min over 10 min. As reported elsewhere this experimental setup was used also for evaluating primary peristalsis and transient lower esophageal sphincter relaxations (6) . In the present study the transmucosal PD values recorded 2 cm oral to the high-pressure zone (the manometric reflection of the lower esophageal sphincter) were analyzed during baseline conditions and during luminal acidification (both situations with manometrically confirmed absence of peristaltic motor activity).
Ussing Chamber Experiments
The resected esophageal specimens were immediately immersed in ice-cold oxygenated (95% O 2 and 5% CO2) Krebs solution with the following composition (in mM): 118.07 NaCl, 4.69 KCl, 2.52 CaCl2, 1.16 MgSO4, 1.01 NaH2PO4, 25 NaHCO3, and 11.10 glucose and transported to the laboratory. The esophageal mucosa was gently removed from the muscular layers by sharp dissection during superfusion with cold oxygenated Krebs solution and was then mounted in a standard vertical Ussing chamber with a 4 ϫ 8 mm oblong opening (Warner Instruments, Hamden, CT). After mounting, each half chamber was filled with 5 ml Krebs solution, bathing both the mucosal and serosal side of the specimen. The Krebs solution was maintained at 37°C and continuously oxygenated with 95% O2 and 5% CO2 and stirred by gas flow in the chambers. Depending on the size of the resected material 2-4 preparations could be retrieved from a single individual. PD was measured with a pair of matched calomel electrodes (REF401, Radiometer Analytical, Copenhagen, Denmark) and the epithelial electrical resistance (Rep) was assessed by use of the Ussing pulse method. The latter has the advantage of specifically estimating Rep and is described in detail elsewhere (22) , for which reason only a brief description is given here: The total resistance in an Ussing chamber is dependent on Rep as well as other in-series coupled electrical resistances, for example in subepithelial tissue that below will be termed "external resistance" (Rext). The Ussing pulse method is based on the fact that the electrical behavior of an epithelium corresponds to a resistor and capacitor in parallel and that active ion transport is to be regarded as a generator of epithelial current (I ep) (10, 12) . To assess R ep, an electrical square-wave current pulse is sent across the mucosal preparation in the Ussing chamber and the voltage response is measured. The pulse character is individualized for each preparation to be between 20 and 100 A with duration of 1 ms to obtain a voltage deflection, preferably between 50 and 100 mV, optimal for analysis as well as an electrical field without significant influence on epithelial functions. Because the epithelium, unlike the rest of the tissue and surrounding baths, has capacitor property (thus in parallel with the electrical resistance of the epithelium; R ep) the voltage recorded following onset or offset of an applied current exhibits two components: first a steep linear change related to external nonepithelial resistance in the system (R ext) and then a second component consisting of a monoexponential leveling off with a time constant related to the epithelial capacitance and resistance (R ep) (22) . Rep is calculated by dividing the height of the voltage deflection of the second component with the applied current. Iep is then calculated by Ohm's Law, where Iep ϭ PD/Rep. In the present setup, data sampling and pulse inductions were computer controlled by using specially constructed hardware and software developed in LabVIEW (National Instruments). As a principle the mean response of three recordings was calculated. Epithelial viability was assessed at the end of each experiment by adding amiloride (a blocker of active Na ϩ transport) into the luminal bath, resulting in a concentration of 10 Ϫ4 M. Only tissues where Iep fell by Ն20% were utilized for data analysis.
After an equilibration period of 30 -45 min, basal parameters were measured over 30 min. After addition of blocking agent (or vehicle as control), an additional baseline period of 15 min was allowed. Ang II was then given stepwise to the serosal bathing solution, increasing the concentrations from 10 Ϫ10 to 10 Ϫ5 M every 5 min in a cumulative manner. Responses to Ang II were tested in absence (ϭ control) or in the presence of the AT 1 receptor selective antagonist losartan (10 Ϫ6 M), or in presence of the AT2-selective antagonist PD123319 (10 Ϫ6 M). The concentrations of agonists and antagonists tested were based on results from previous studies on human muscular preparations in vitro (6, 8, 21) . In addition the selective nonpeptide AT 2 receptor agonist compound 21 (C21) was added in a separate series (29) . Each mucosal sample served as its own control.
Drugs and Chemicals
The following chemicals were used in the in vitro study: Ang II; PD123319 and amiloride (Sigma Chemical, St. Louis, MO); losartan (Merck); and C21 (gift from Dr. A. Hallberg, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden), were all dissolved in Krebs solution. In the in vivo study the AT1 receptor antagonist candesartan (Atacand, AstraZeneca, Mölndal, Sweden) was used (dose and administration given above).
Data Analysis and Statistics
Kruskal-Wallis and Mann-Whitney U-test for unpaired values or Friedman and Wilcoxon's signed rank test for paired value were used in the statistical analysis by use of the SPSS statistical software (SPSS, Chicago, IL). A value of P Ͻ 0.05 was considered to be statistically significant. In the in vitro experiments group differences were determined from pEC50 value (negative logarithm of molar concentration of Ang II producing 50% of the maximal response, as interpolated from the individual concentration-response relationship) in the presence or absence of the antagonists by use of a nonlinear sigmoid regression (GraphPad Prism 4.0; GraphPad Software, San Diego, CA).
RESULTS
Expression of RAS in Human Esophageal Mucosa
Immunohistochemistry performed on endoscopically retrieved mucosal biopsies and resected tissue revealed a distinct staining for ACE in the capillary walls located at the tip of the papillae and in the blood vessel walls in the lamina propria (Fig. 1A) . Immunostaining for AT 1 receptors was detected in the epithelium and most obvious in stratum superficiale and spinosum (Fig. 1B) . AT 1 receptor immunoreactivity was also detected in the blood vessel walls supplying the epithelium and in the lamina propria. Immunostaining for AT 2 receptors was detected in the epithelium and, similar to AT 1 receptor, most distinctly in stratum superficiale and spinosum as well as in blood vessel walls supplying the epithelium in the lamina propria (Fig. 1C) . In both cases the lamina propria papillae were negative. Negative controls remained unstained in all specimens (example given in Fig. 1D ). Western blotting exhibited a strong AT 1 and AT 2 receptor immunoreac- Fig. 2 . A: typical Western blot for AT1 receptor with a band at 41 kDa in the positive control cell lysate PC12 and in human esophageal mucosa retrieved from a healthy volunteer during endoscopy (S1) and from surgical esophagectomy (S2). B: Western blotting of the AT2 receptor with a band at 44 kDa in the positive control cell lysate Hep G2 and in samples S1 and S2. C: ACE analysis with a band at 195 kDa in the positive control cell lysate kidney extract and in samples S1 and S2. PCR results are given as copy numbers of target genes per microgram of total RNA. Western blot results are given as a quota of optical density of the sample and gel standard. Data are presented as median value and ranges; n, number of patients. RAS, renin-angiotensin system. tivity (Fig. 2, A and B) , whereas only a faint staining of ACE was detected in the esophageal mucosal tissue samples (Fig. 2C) . Expressions of gene transcripts and proteins, respectively, were of similar order of magnitude independent of whether the biopsies were retrieved from endoscopic investigations or from resected esophagii ( Table 2) .
Transmucosal PD Measurements In Vivo
By use of the pressure profile obtained from the intraesophageal manometric catheter the high-pressure zone (hpz) corresponding to the lower esophageal sphincter was identified. PD values at a level 2 cm oral to the hpz were used for analysis. Baseline esophageal PD values differed markedly between individuals, ranging from Ϫ3.5 to Ϫ30 mV. The PD values after intake of the AT 1 receptor antagonist candesartan were significantly higher (more lumen negative) compared with control level (P ϭ 0.032) (Fig. 3A) .
Luminal perfusion with hydrochloric acid (HCl, 100 mM with NaCl 50 mM to obtain isotonicity) elicited a transient increase in PD with a peak appearing after 4 -5 min. PD then slowly declined to reach baseline values after 15-20 min. The delta PD response (peak minus baseline) to HCl perfusion was significantly larger after intake of candesartan compared with controls (P ϭ 0.032, data not shown in figure) . Because both baseline PD and the HCl-induced PD change increased, it follows that the acid-induced peak PD was higher in all except one case after candesartan administration (P ϭ 0.013) (Fig. 3B) .
In Vitro Analysis Using the Ussing Chamber Technique
Time control and baseline. After mounting and a 30-to 45-min equilibration period, the prepared mucosa remained electrically stable for upward of 2 h (n ϭ 2). In the pharmacological experiments baseline values of PD, R ep , and I ep were measured over 30 min, after which Ang II receptor blocking agents (losartan or PD123319) or vehicle were added. Neither of the two blocking agents significantly influenced baseline values, as shown in Table 3 . After another 15 min the agonists Ang II or C21 were given stepwise as described in MATERIALS AND METHODS.
Effects of Ang II and interference with the subreceptor. Ang II added to the serosal side in the chamber caused a Fig. 3 . Esophageal transmucosal potential difference (PD) measurements during control and after a single 16-mg dose of candesartan in healthy volunteers (n ϭ 13) on 2 separate study days. A: basal PD values were significantly higher after intake of candesartan. B: the PD peak value during luminal perfusion with 100 mM HCl was higher after candesartan administration. The median value in each group is indicated; *significant difference, P Ͻ 0.05. concentration-dependent rise of both PD and I ep , with maximal values ϳ20% above baseline (P ϭ 0.001 and 0.003, respectively), whereas no significant effect on R ep was observed (Fig. 4) .
Ang II given in presence of the AT 1 receptor antagonist losartan (10 Ϫ6 M) induced a response pattern that did not differ from when Ang II was given alone: PD increased 20% (pEC50 for control 9.59 Ϯ 1.0; losartan 8.96 Ϯ 0.96; P ϭ 0.74) and I ep increased some 12% (pEC50 for control 9.79 Ϯ 1.2 and for losartan 9.72 Ϯ 1.1; P ϭ 0.97). R ep was not influenced (Fig. 4) .
Selective AT 2 receptor stimulation was performed by use of the nonpeptide AT 2 receptor agonist C21. A similar response pattern, although less pronounced, was obtained by C21 when given in two concentrations (0.1 and 1.0 M) on the serosal side. Thus C21 increased significantly PD as well as I ep compared with the baseline (P ϭ 0.016 and 0.028, respectively) but left R ep constant (Fig. 5) .
Adding Ang II in presence of the selective AT 2 receptor antagonist PD123319 (10 Ϫ6 M, serosal side) induced no significant effect on PD, whereas I ep decreased 10 -12% (P ϭ 0.047) and R ep increased by ϳ15% (P ϭ 0.01) (Fig. 4) . 
DISCUSSION
This study represents the first evidence that the RAS is expressed and functional in the esophageal mucosa in humans. Immunoreactivity to AT 1 and AT 2 receptors was found in the surface epithelium, whereas ACE appeared in capillary walls located at the tip of the papillae and in blood vessel walls in the lamina propria. This topographical organization of RAS components in the esophageal mucosa is of great interest with regard to functionality. The vascular localization of ACE suggests that Ang II formation is localized in the lamina propria close to the epithelium. Consequently, Ang II can, in high local concentrations, easily reach its epithelial receptors. To test these morphological findings from a functional perspective, healthy volunteers were given a single dose of the selective AT 1 receptor antagonist candesartan. This treatment raised both baseline and acid-induced esophageal transmucosal electrical PD (i.e., lumen negativity became more pronounced after administration), indicating impact on the epithelial functional state. Measurement of esophageal transmucosal PD has been used to reflect the functional state and integrity of the epithelium (5, 19) . Recording PD is a safe and quite simple procedure that is suitable for research in humans for exploratory reasons. However, one obvious disadvantage is that because PD is composed of several interacting components it is difficult to differentiate between the mechanisms of actions involved. In principle, baseline transmucosal PD is a function of the I ep generated by the epithelium due to ion-movements, and of R ep determined mainly by paracellular conductivity. Both I ep and R ep are of great interest from a regulatory point of view but cannot be discerned from a single PD recording. It becomes even more complicated if the luminal ionic composition changes. Exposure of the mucosa to high luminal acidity is a classical provocation test ("the Bernstein test") to induce gastroesophageal reflux symptoms (3). Normally, transmucosal PD increases when the mucosa is exposed to acid (5) . This may be due to luminal acidity influencing the epithelial functional state, but in the short term the altered luminal physicochemical conditions are probably even more important (14) . During acidification the cationic luminal composition changes to a dominance of the H ϩ instead of Na ϩ , adding a pronounced diffusion potential to the epithelial PD. The recorded magnitude of this diffusion potential is dependent on the electrical properties of the mucosa, i.e., I ep and R ep (5) . It follows that it cannot be decided whether the observed changes in basal and acid-induced PD following candesartan intake were due to influencing I ep or R ep (or both). In any case, the fact that both basal PD and the acid-induced PD increment changed following candesartan strongly indicates involvement of endogenous Ang II in regulating epithelial functions. However, interferences with RAS in vivo are complicated also for pharmacological reasons. Although candesartan is a very selective AT 1 receptor antagonist, it is not evident that effects observed following its administration are due to interference only with this Ang II subreceptor. Effects observed following administration of an AT 1 receptor antagonist could also be due to actions by Ang II on the simultaneously unopposed AT 2 receptor (7, 15, 28) . The pharmacological background to this phenomenon deserves some explanation: Systemic administration of a selective AT 1 receptor antagonist results in two important effects, the obvious blockade of the AT 1 receptors and, as a result of the former, blockade of feedback inhibition of renin release resulting in increased renin activity. Being the main rate-limiting factor for Ang II formation, the increased renin activity results in an accelerated degradation of the circulating prohormone angiotensinogen to the decapeptide angiotensin I, which in turn will be degraded to the bioactive octapeptide Ang II by ACE (and other enzymes, e.g., chymase).
The AT 1 receptor antagonist used in this study, candesartan, is a commonly prescribed antihypertensive and was given as a single dose that previously has been reported to increase renin release (2, 11) . It is therefore reasonable to assume that endogenous Ang II formation increased markedly following the AT 1 receptor antagonism and that the increased Ang II concentrations targeted mainly the AT 2 receptor. However, it cannot be excluded that AT 1 receptor interference raised transmucosal PD in the present study also by unloading AT 1 receptors. Because there are no pharmaceuticals available for clinical use targeting the AT 2 receptor, the evaluation of Ang II subreceptor involvement was performed in vitro in Ussing chambers. One advantage with experimentation on isolated mucosa in vitro is that concentration-response curves can be recorded from a baseline without background (endogenous) Ang II formation. In the present study we used conventional Ussing chambers demanding rather large esophageal specimens to provide stable experimental conditions. The mucosal tissue from the distal esophagus was obtained at surgical resections due to mucosal neoplasms. Great attention was paid to secure that the tissue under study was morphologically normal. It was also confirmed that gene and protein expressions of RAS components were present to the same degree and localization in resected tissues as observed in endoscopic biopsies from healthy volunteers. Indeed, the in vitro study confirmed that Ang II influenced electrical parameters of the human esophageal mucosa via both the AT 1 and the AT 2 receptor subtypes. Administration of Ang II per se resulted in increased lumen negative PD due to an increased I ep whereas R ep was rather constant, indicating an increased lumen-directed net flux of anions or a serosally directed flux of cations. Because an identical response pattern was obtained also in presence of the AT 1 receptor antagonist losartan, activation of AT 1 receptors cannot be the dominant mechanism of action. Instead, the observed Ang II induced effects are to be ascribed to activation of AT 2 receptors. This interpretation was strongly supported by the finding that selective AT 2 -receptor stimulation by the agonist C21 was also associated with an increased PD due to an increased I ep , without any apparent effect on R ep .
Interestingly, Ang II given in presence of the selective AT 2 antagonist PD123319 (thus a condition compatible with a selective AT 1 receptor stimulation) decreased I ep and increased R ep , with the result that PD did not change significantly. These results are consistent with the existence of AT 1 receptormediated reductions of electrogenic ion transport and paracellular permeability.
The electrical negativity recorded in the esophageal lumen is mainly due to active transport of Na ϩ from lumen into the mucosa (1, 18, 25) . It is therefore tempting to suggest that activation of esophageal epithelial AT 2 receptors increases Na ϩ absorption resulting in a more pronounced lumen negativity. In addition, bicarbonate secretion by the esophageal mucosa may constitute an alternative target for AT 2 receptor stimulation (26), as previously described for the rat duodenal mucosa (15, 29) . Further studies are needed to confirm these possibilities and also to pinpoint which of several possible ion transport mechanisms (24) are involved. Although the present study indicates a physiological role for RAS in the esophageal mucosa, the degree of clinical significance with regard to, for example, epithelial resistance to acidification and other luminal aggressors related to gastroesophageal reflux remains to be investigated. In addition, in the renocardiovascular system Ang II is ascribed an important role for promoting tissue proliferation and differentiation (7) . Recent epidemiological data show that antihypertensive treatment with ACE inhibition is associated with a lower incidence of esophageal adenocarcinoma than are antihypertensive therapies that do not interfere with RAS (20) . These intriguing data suggest an involvement of RAS in esophageal mucosal carcinogenesis. The presently reported subepithelial localization of ACE and epithelial localization of the Ang II subreceptors in the healthy human mucosa make it of considerable interest to investigate expression of RAS in chronic reflux disease, including also columnar lined esophagus with premalignant dysplasia, and possible associations to biomarkers of carcinogenesis.
In summary, this exploratory study shows that key components (ACE, AT 1 receptor, and AT 2 receptor) of RAS have a functional topographical expression in the healthy human esophageal mucosa. Pharmacological interference with the AT 1 receptor raised transmucosal PD in healthy volunteers, and an in vitro analysis indicated that this response was mainly due to indirect activation of AT 2 receptor influencing epithelial ion-transport mechanisms. The AT 1 receptor appears to be involved in regulating paracellular conductivity. Future studies are needed to further elucidate the physiological and possible clinical significance of RAS as a regulatory system of the human esophageal epithelium.
